Ronshine China (3301) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
31 Aug, 2026Executive summary
Contracted sales for the six months ended 30 June 2026 were RMB1,293.88 million, down 38.62% year-over-year, with contracted GFA of 113,105 sq.m. and average selling price of RMB11,440 per sq.m.
Revenue fell 62.35% year-over-year to RMB798.91 million, mainly due to a sharp decline in property deliveries.
Gross profit dropped 91.67% to RMB47.02 million, with gross margin narrowing to 5.89% from 26.61%.
Loss for the period widened to RMB1,915.48 million, with loss attributable to owners at RMB1,565.11 million.
The Group continues to focus on core regions, maintain prudent development, and manage liquidity amid industry headwinds.
Financial highlights
Revenue: RMB798.91 million, down 62.35% year-over-year.
Gross profit: RMB47.02 million, down 91.67% year-over-year.
Gross margin: 5.89% (vs. 26.61% prior year).
Loss for the period: RMB1,915.48 million (vs. RMB1,704.13 million prior year).
Loss attributable to owners: RMB1,565.11 million (improved from RMB1,829.16 million prior year).
Net current liabilities: RMB25,749.55 million as of 30 June 2026.
Cash and bank balances: RMB2,332.94 million; total borrowings: RMB35,954.27 million.
Outlook and guidance
The real estate market is expected to remain in a phase of deep adjustment and optimisation in the second half of 2026.
The Group will continue focusing on core regions, enhancing operational efficiency, and prudent cash flow management.
Ongoing efforts to ensure on-time property delivery and seize market opportunities.
Latest events from Ronshine China
- Severe revenue decline and mounting losses led to an auditor disclaimer over going concern.3301
H2 2025 - Revenue fell 85% and a net loss of RMB1.7 billion was recorded amid severe liquidity stress.3301
H1 2025 - Revenue up, profit positive, but sales and liquidity risks remain amid ongoing debt defaults.3301
H1 2024 - Sharp revenue drop and deepening losses raise significant going concern risks.3301
H2 2024